Patterns of antibiotic use, pathogens and clinical outcomes in hospitalised neonates and young infants with sepsis in the NeoOBS global neonatal sepsis observational cohort study

Neal Russell*, Wolfgang Stöhr*, Nishad Plakkal, Aislinn Cook, James A Berkley, 4,5,6 Bethou Adhisivam, Ramesh Agarwal, ⁷ Manica Balasegaram ⁸ Daynia Ballot, ⁹ Adrie Bekker, ¹⁰ Eitan Naaman Berezin, ¹¹ Davide Bilardi, 12 Suppawat Boonkasidecha, 13 Cristina G. Carvalheiro, 14 Suman Chaurasia, 15 Sara Chiurchiu, 16 Simon Cousens, ¹⁷ Tim R. Cressey, ¹⁸ Tran Minh Dien, ¹⁹ Yijun Ding, ²⁰ Angela Dramowski, ¹⁰ Madhusudhan DS, ²¹ Ajay Dudeja, ²² Jinxing Feng, ²³ Youri Glupczynski, ²⁴ Herman Goossens, ²⁴ Tatiana Munera Huertas, ¹ Mohammad Shahidul Islam, 25 Daniel Jarovsky, 11 Nathalie Khavessian, 8 Meera Khorana, 26 Tomislav Kostyanev, 24 Mattias Larsson, 27 Maia De Luca, 16 Surbhi Malhotra-Kumar, 24 Marisa M. Mussi-Pinhata, 14 Ruchi Nanavati, 21 Sushma Nangia,²² Jolly Nankunda,²⁸ Alessandra Nardone,¹² Borna Nyaoke,⁸ Christina W Obiero,^{4,29} Maxensia Owor,²⁸ Wang Ping, 30 Kanchana Preedisripipat, 31 Shamim Qazi, 32 Tanusha Ramdin, 9,33 Amy Riddell, Emmanuel

¹ Center for Neonatal and Paediatric Infection (CNPI), Institute of Infection & Immunity, St George's University of London

² Medical Research Council Clinical Trials Unit at University College London, London, UK

³ Department of Neonatology, Jawaharlal Institute of Postgraduate Medical Education & Research (JIPMER), Pondicherry,

⁴ Clinical Research Department, KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya

 $^{^{5}}$ Centre for Tropical Medicine & Global Health, Nuffield Department of Medicine, University of Oxford, Oxford UK

The Childhood Acute Illness & Nutrition (CHAIN) Network, Nairobi, Kenya

⁷ Newborn Division and WHO-CC, All India Institute of Medical Sciences, New Delhi, India.

⁸ Global Antibiotic Research and Development Partnership (GARDP), Geneva, Switzerland

⁹ Department of Paediatrics and Child Health, Chris Hani Baragwanath Academic Hospital, School of Clinical Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.

10 Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, South

Africa

11 Pediatric Infectious Diseases Unit, Santa Casa de São Paulo, Rua Dr. Cesário Mota Júnior 112, São Paulo, SP 01221-020,

Brazil

¹² Penta Foundation, Padova, Italy

¹³ Queen Sirikit National Institute of Child Health, Bangkok, Thailand

Department of Pediatrics, Ribeirão Preto Medical School, University of São Paulo, Brazil

¹⁵ All India Institute of Medical Sciences, Department of Paediatrics, New Dehli, India

¹⁶ Academic Hospital Paediatric Department, Bambino Gesù Children's Hospital, Rome, Italy

¹⁷ Faculty of Epidemiology and Population Health, Department of Infectious Disease Epidemiology, London School of Hygiene & Tropical Medicine

¹⁸ PHPT/IRD-MIVEGEC, Faculty of Associated Medical Sciences, Chiang Mai University, Thailand

¹⁹ Vietnam National Children's Hospital, Hanoi, Vietnam and Surgical intensive care unit, Vietnam National Children's Hospital, Hanoi, Vietnam

²⁰ Department of Neonatology, Beijing Children's Hospital, Capital Medical University, National Centre for Children's Health, Beijing, China

¹ Neonatology Department, Seth GS Medical College and King Edward Memorial Hospital, Mumbai, India.

Department of Neonatology, Lady Hardinge Medical College & associated SSK & KSC Hospitals, New Delhi

Department of Neonatology, Shenzhen Children's Hospital, Shenzhen, China

²⁴ Laboratory of Medical Microbiology, University of Antwerp, Antwerp, Belgium

²⁵ Child Health Research Foundation (CHRF), Dhaka Shishu Hospital, Dhaka, Bangladesh

²⁶ Neonatal Unit, Department of Pediatrics, Queen Sirikit National Institute of Child Health, College of Medicine, Rangsit University, Bangkok, Thailand

⁷ Department of Global Public Health, Karolinska Institutet, Stockholm, Sweden

Makerere University - Johns Hopkins University Research Collaboration, Kampala, Uganda

Amsterdam UMC, University of Amsterdam, Emma Children's Hospital, Department of Global Health, Amsterdam, the Netherlands.

³⁰ Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing, China

Chiangrai Prachanu kroh Hospital, Chiang Rai, Thailand

³² World Health Organisation, Maternal, Newborn, Child and Adolescent Health Department, Geneva, Switzerland

³³ Department of Paediatrics and Child Health, Charlotte Maxeke Johannesburg Academic Hospital, Johannesburg, South Africa

Roilides, ³⁴ Samir K Saha, ²⁵ Kosmas Sarafidis, ³⁵ Reenu Thomas, ³⁶ Sithembiso Velaphi, ⁹ Tuba Vilken, ²⁴ Yajuan Wang, ³⁷ Yonghong Yang, ²³ Liu Zunjie, ³⁰ Sally Ellis, ⁸ Julia Bielicki, ¹ A Sarah Walker, ² Paul T. Heath, ¹ Mike Sharland, ¹ *Co-First authors, listed alphabetically

³⁴ Infectious Diseases Unit, 3rd Dept Pediatrics, School of Medicine, Faculty of Health Sciences, Aristotle University and Hippokration General Hospital, Thessaloniki, Greece

³⁵ Neonatology Dept, School of Medicine, Faculty of Health Sciences, Aristotle University and Hippokration General Hospital, Thessaloniki, Greece

³⁶ School of Clinical Medicine, Faculty of Health Sciences, University of the Witwatersrand

³⁷ Department of Neonatology, Children's Hospital, Capital Institute of Pediatrics, Yabao Road, Chaoyang District, Beijing, China

<u>Abstract</u>

1

2

Background

- 3 Neonatal sepsis is a leading cause of child mortality, and increasing antimicrobial resistance
- 4 threatens progress towards the Sustainable Development Goals. Evidence to guide antibiotic
- 5 treatment for sepsis in neonates and young infants from randomized controlled trials or
- 6 observational studies in low- and middle-income countries (LMICs) is scarce. We aimed to describe
- 7 patterns of antibiotic use, pathogens and outcomes in LMIC hospital settings globally to inform
- 8 future clinical trials on the management of neonatal sepsis.
- 9 Methods & Findings
- 10 Hospitalised infants aged <60 days with clinical sepsis were enrolled during 2018-2020 by 19 sites in
- 11 countries (mainly Asia and Africa). Prospective daily data was collected on clinical signs,
- 12 supportive care, antibiotic treatment, microbiology and clinical outcome at 28 days. The study was
- observational, with no changes to routine clinical practice. 3204 infants were enrolled, with median
- 14 birth weight 2500g (IQR 1400-3000) and postnatal age 5 days (IQR 2-15). Of 309 enrolled aged 28-60
- days, 58.6% (n=181) were ex-preterm and/or a neonate at admission. 2215 (69%) infants had been
- in hospital since birth.
- 17 206 different empiric antibiotic combinations were used, which were structured into 5 groups that
- 18 were developed from the World Health Organisation (WHO) AWaRe classification. 25.9% (n=814) of
- infants started a WHO first line regimen (Group 1 -Access, penicillin-based regimen) and 13.8%
- 20 (n=432) started WHO second-line cephalosporins (cefotaxime/ceftriaxone) (Group 2- 'Low' Watch).
- 21 The largest group (34.0%, n=1068) started a regimen providing partial extended-spectrum beta-
- 22 lactamase (ESBL)/pseudomonal coverage (piperacillin-tazobactam, ceftazidime, or fluoroquinolone-
- 23 based) (Group 3 'Medium' Watch), 18.0% (n=566) started a carbapenem (Group 4 'High' Watch),
- and 1.8% (n=57) started a Reserve antibiotic (Group 5, largely colistin-based). Predictors of starting
- 25 non-WHO recommended regimens included lower birth weight, longer in-hospital stay, central
- 26 vascular catheter use, previous culture positive sepsis or antibiotic exposure, previous surgery and
- 27 greater sepsis severity. 728/2880 (25.3%) of initial regimens in Group 1-4 were escalated, mainly to
- carbapenems, and usually for clinical indications (n=480; 65.9%).
- 29 564 infants (17.6%) isolated a pathogen from their baseline blood culture, of which 62.9% (n=355)
- 30 had a Gram-negative organism, predominantly Klebsiella pneumoniae (n=132) and Acinetobacter
- 31 spp. (n=72). These leading Gram-negatives were both mostly resistant to WHO-recommended
- 32 regimens, and also resistant to carbapenems in 32.6% and 71.4% of cases respectively. MRSA
- accounted for 61.1% of Staphylococcus aureus (n=54) isolates.
- 34 Overall, 350/3204 infants died (11.3%; 95%Cl 10.2-12.5%), with 17.7% case fatality rate among
- infants with a pathogen in baseline culture (95%CI 14.7-20.1%, n=99/564). Gram-negative infections
- accounted for 75/99 (75.8%) of pathogen-positive deaths, especially Klebsiella pneumoniae (n=28;
- 37 28.3%), and *Acinetobacter* spp. (n=24; 24.2%).
- 38 Conclusion
- 39 A very wide range of antibiotic regimens are now used to treat neonatal sepsis globally. There is
- 40 common use of higher-level Watch antibiotics, frequent early switching and very infrequent de-
- 41 escalation of therapy. Future hospital based neonatal sepsis trials will ideally need to account for the
- 42 multiple regimens used as standard of care globally and include both empiric first line regimens and
- subsequent switching in the trial design.

44 45 **Author Summary** 46 47 Why was this study done? 48 Increasing trends in antimicrobial resistance (AMR) disproportionately affect neonates and 49 young infants with sepsis in LMIC settings and undermine the effectiveness of WHOrecommended antibiotics. 50 > Despite this, longitudinal data on antibiotic management strategies and outcomes of 51 52 affected hospitalised neonates and young infants in LMIC settings are extremely limited, 53 impeding the design of robust antibiotic trials. 54 What did the researchers do and find? 55 > To our knowledge this is the first global, prospective, hospital-based observational study of 56 clinically diagnosed neonatal sepsis across 4 continents including LMIC settings, with daily data on clinical status, antibiotic use and outcomes. 57 58 > There was a high mortality among infants with culture positive sepsis (almost 1 in 5), and a significant burden of antibiotic resistance. 59 > This study highlights wide variations in standard of care for sepsis in neonates and young 60 infants with more than 200 different antibiotic combinations, significant divergence from 61 62 WHO-recommended regimens, and frequent switching of antibiotics. 63 What do these findings mean? 64 > These data demonstrate that patterns of routine antibiotic use are now markedly divergent 65 from global guidance 66 > There is an urgent need for randomised controlled trials to address optimal empiric first and 67 second line antibiotic treatment strategies in LMIC hospital settings with a significant AMR 68 69 Data from this study can inform the design of multicentre hospital-based neonatal antibiotic 70 trials in LMIC settings. > The wide range of multiple antibiotic regimens routinely used as Standard of Care (SOC) 71 72 suggests the need for novel trial designs. 73

74

75 76

<u>Introduction</u>

79

- 80 Sepsis is responsible for a significant burden of disease in neonates and young infants, both as a
- primary cause of death, and as a frequent contributor. ¹² Access to facility-based delivery and care,
- 82 including antibiotics, has not consistently reduced mortality to the extent necessary to achieve the
- 83 Sustainable Development Goal targets in many low and middle income countries (LMICs).³
- 84 Antimicrobial resistance (AMR) increasingly threatens to undermine the effectiveness of antibiotics
- and potentially slows the progress in reducing mortality, particularly in LMICs, ^{4–10} with AMR-
- attributable neonatal deaths recently estimated between 140,000¹⁰ and 214,000.¹¹
- 87 Recent large scale antibiotic trials in neonates and young infants in LMIC settings have largely
- 88 focused on simplification of first line antibiotic regimens with oral amoxicillin and short course
- 89 gentamicin. 12,13 These have been based in community settings and included populations with
- 90 mortality below 2%. However, an increasing global proportion of new-borns are delivered in facilities
- 91 (~3/4),14 where sepsis case fatality rates and the burden of AMR are greater. Despite this, there is
- 92 limited high quality evidence generated in LMIC neonatal inpatient settings to guide empiric
- antibiotic treatment. 4,15 Published observational data largely involve single centre studies reporting
- 94 non-systematically collected microbiological data, which are rarely accompanied by detailed clinical
- and antibiotic use data. Global antibiotic use data largely rely on point prevalence surveys, with
- limited information on patterns of switching and duration.¹⁶
- 97 In this paper we describe a prospective multi-country observational study in which we collected
- 98 detailed daily longitudinal data on clinical features, microbiology, antibiotic use and switching, and
- outcomes of neonatal sepsis in hospital settings, predominantly in LMICs. The primary aim was to
- describe the variation and patterns of hospital-based antibiotic use to inform the design of hospital
- based neonatal sepsis antibiotic trials and future guidance. 17

Methods

102

103

104

Study design and participants

- Hospitalized infants <60 days of age with a new episode of clinically suspected sepsis were enrolled
- between 2018 and 2020, in 19 hospital sites across 11 countries in Asia (Bangladesh, China, India,
- 107 Thailand and Vietnam), Africa (Kenya, South Africa, Uganda), Europe (Italy, Greece) and South
- 108 America (Brazil). Sites were selected after conducting a feasibility study¹⁸ to represent diverse
- 109 regions and to include secondary and tertiary referral hospitals, public facilities, and facilities with
- varying proportions of in-born and out-born neonates, with access to microbiology.
- 111 Infants were eligible if the local physician had decided to treat the infant with antibiotics for a new
- episode of sepsis meeting the inclusion criteria (supplement figure 1), derived by combining clinical
- and laboratory criteria from WHO possible Serious Bacterial Infection (pSBI)¹⁹ and EMA Criteria for
- neonatal sepsis trials.²⁰ To allow for variation in access to laboratory testing, and ensure
- generalizability to varying LMIC hospital contexts, laboratory values were not mandatory. A
- minimum of 2 clinical, or 1 clinical and 1 laboratory sepsis criteria, were required for inclusion, and
- 117 up to 200 infants per site were enrolled according to a sampling frame adapted to local case volume
- and activity. Infants were excluded if an alternative primary diagnosis other than sepsis was
- suspected, or a serious non-infective comorbidity was expected to cause death within 72 hours.
- 120 Previous antibiotic use was not an exclusion criterion as long as a new antibiotic regimen was being
- started after a blood culture for a distinct new episode of sepsis. Sepsis episodes occurring >48 hours

after admission, defined by time of blood culture, were considered healthcare-associated infections (HAI). Ethical approval was obtained from St. George's, University of London (SGUL) Research Ethics Committee and sites' local, central or national ethics committees and other relevant local bodies, where required. Design and reporting were guided by the STROBE-NI framework, 21 and the trial was registered with ClinicalTrials.gov (NCT03721302). **Procedures** After consent from parents, baseline demographic and clinical data were collected, followed by prospective daily collection of observational data including multiple clinical parameters, laboratory investigations and microbiological results. Antibiotic data were collected daily including drug, dose, route, duration, switching and reasons given for any changes. Clinical data collection was required up to 48 hours after the completion of antibiotic therapy or discharge if sooner. Aside from a mandatory blood culture at enrolment and daily monitoring of vital signs, all clinical observations and investigations were performed according to routine local site practices. Infants were followed until 28 days after enrolment in-person if still hospitalized, or by telephone post-discharge. A final diagnosis was documented by clinicians, as were primary and secondary causes of death, and any clinical illness or readmission occurring after discharge and within 28 days of enrolment. Data were collected by research and clinical staff based on clinical observation and routine source documentation (e.g. medical and nursing notes, vital signs and prescription charts), and entered and managed using REDCap™ electronic data capture tools²² hosted at SGUL (details on data monitoring in supplementary appendix.) Microbiology/Laboratory assessments Laboratory analysis was performed in each site following local practice, with standard operating procedures developed to optimise procedures including blood culture technique, and antibiotic susceptibility testing. A locally defined algorithm was used to classify contaminants and pathogens by site clinicians and microbiologists. External validation of the capability of laboratories to detect multi-drug resistant (MDR) Gram-negative pathogens from each site was evaluated objectively by testing an external quality assurance (EQA) panel sent from the central laboratory at Laboratory of Medical Microbiology (LMM) at the University of Antwerp (UA). European Committee on Antimicrobial Susceptibility Testing (EUCAST) or Clinical and Laboratory Standard Institute (CLSI) guidelines and interpretive algorithms were used to interpret reported antibiotic susceptibility testing data for all organisms. EUCAST 2019 breakpoints table (v9.0) and guidelines were used as this was the year the majority of the data was reported. In most cases, where susceptibility to a particular antibiotic was reported, this was used to determine susceptibility. If the organism was considered intrinsically resistant to a particular antibiotic

according to EUCAST, then it was coded as resistant regardless of reported susceptibility. If

reported susceptibility then susceptibility was coded as unknown.

susceptibility to a particular antibiotic was not reported, susceptibility results of a different antibiotic

aminoglycoside if gentamicin susceptibility was not reported); if no other antibiotic in that class had

in the same class were used to determine susceptibility (e.g. susceptibility of organism to another

Analysis of antibiotic patterns of use

122

123

124

125

126 127

128

129

130

131

132

133

134

135

136

137

138

139

140

141142

143

144

145

146

147

148

149

150

151

152153

154

155

156

157

158

159

160

161

162

164 The initial antibiotic regimen was defined as the first new antibiotic(s) started within 24 hours from 165 baseline blood culture (including 3 hours pre baseline culture). To structure the analysis and 166 reporting of the multiple regimens used, a novel method of grouping antibiotics was derived, based 167 on the Essential Medicine List for Children (EMLc) AWaRe classification (Access, Watch, Reserve; supplementary appendix),²³ with the 'Watch' category divided into 3 distinct groups of 168 169 'Low/Medium/High Watch' based on inclusion in current WHO guidelines (Low Watch) and 170 likelihood of resistance generation in regimens outside WHO recommendations (Medium or High 171 Watch). 24 Antibiotic groups were defined by the main 'stem' in the antibiotic combination: Group 1 antibiotics included a first line WHO recommended penicillin-based regimen (e.g., ampicillin and 172 gentamicin) (Access), Group 2 included 3rd generation cephalosporin (eg cefotaxime/ceftriaxone)-173 based WHO regimens ('Low' Watch), Group 3 included regimens with partial anti-extended-174 175 spectrum beta-lactamase ((ESBL) or pseudomonal activity (e.g. piperacillin-176 tazobactam/ceftazidime/fluoroquinolone-based) ('Medium' Watch), and Group 4 included 177 carbapenems (e.g., meropenem) ('High' Watch). Group 5 antibiotics included Reserve antibiotics 178 targeting carbapenem resistant organisms (e.g. colistin). Aminoglycosides (e.g. 179 gentamicin/amikacin), glycopeptides (e.g. vancomycin/teicoplanin) and metronidazole used in 180 combination regimens were classified as additional coverage and did not define the main antibiotic 'stem' for the grouping. All antifungals and antivirals were excluded from the antimicrobial 181 182 treatment data as these were not relevant to the analysis. Escalation of treatment was defined as a 183 switch to a higher group antibiotic, and de-escalation was defined as switching to a lower group or 184 discontinuation of the 'stem' antibiotic whilst continuing with an additional coverage antibiotic.

Statistical analysis

185

186

187

188

189

190

191

192 193

194

195

196

197

198

199

200

201

The pre-specified primary outcome was mortality through 28 days post-enrolment, analysed using Kaplan-Meier and Cox proportional hazards regression with site-level random effects. Time was measured from the initial blood culture sample, censoring at the earliest of day 28, withdrawal or last contact if lost post-discharge. To analyse whether time from baseline culture to the start of new antibiotic regimen or type of pathogen were associated with mortality, respectively, we adjusted for previously established baseline predictors of mortality (Submitted manuscript²⁵). Multivariable logistic regression with backwards elimination (exit p=0.05) adjusted for site was used to analyse factors associated with starting group 3-5 versus group 1-2 regimens in sites with at least 10% of infants in either. Candidate factors were known at sepsis presentation and included birth weight, gestational age, postnatal age, time in hospital, central line or indwelling catheter, Intravenous (IV) antimicrobials in previous 24 hours, signs of meningitis, previous positive culture, previous surgery, and a score reflecting sepsis severity (Submitted manuscript²⁵). Cumulative incidence antibiotic escalation or stop of all iv antibiotics was estimated with death as competing risk.

Analyses used Stata version 16.1.

Role of the funding source

This study was funded by the Global Antibiotic Research and Development Partnership (GARDP),
made possible by Bill & Melinda Gates Foundation; German Federal Ministry of Education and
Research; German Federal Ministry of Health; Government of the Principality of Monaco; the Indian
Council for Medical Research; Japanese Ministry of Health, Labour and Welfare; Netherlands
Ministry of Health, Welfare and Sport; South African Medical Research Council; UK Department of
Health and Social Care (UK National Institute of Health Research and the Global Antimicrobial
Resistance Innovation Fund – GAMRIF); UK Medical research Council; Wellcome Trust. GARDP has

Resistance Innovation Fund – GAMRIF); UK Medical research Council; Wellcome Trust. GARDP has

209 also received core funding from the Leo Model Foundation; Luxembourg Ministry of Development 210 Cooperation and Humanitarian Aid; Luxembourg Ministry of Health; Médecins Sans Frontières; Swiss 211 Federal Office of Public Health; UK Foreign, Commonwealth & Development Office (previously the 212 UK Department for International Development). 213 The authors had access to all study-related data and had final responsibility for publication. 214 **Results** 215 216 3204 infants (90.4% neonates aged <28 days, n=2895; 42.1% female, n=1348) were recruited from 217 20th August 2018 - 29th February 2020 (table 1; supplement figure 2). Sites included varying 218 populations of infants, and levels of care (see supplement figures 3-5). The median postnatal age 219 was 5 (IQR 1-15) days, and 3088 (96.4%) infants had been born in a hospital/facility (1550 in the 220 enrolling facility), 1412 (44.3%) by caesarean section (969 as an emergency). 71 (2.2%) had 221 previously been treated for an episode of culture-positive sepsis. The median (IQR) gestational age 222 at birth was 37 (31-39) weeks, with birth weight 2500g (1400-3000g). At enrolment, 69.1% (n=2215) 223 infants had been hospitalised since birth, and 30.9% (n=989) were admitted from the community. 224 2759 (86.1%) were recruited in a neonatal unit. Among 309 (9.6%) infants enrolled aged ≥28 days, 225 the majority (n=181; 58.6%) were either ex-premature (n=146; 47.4%) and/or had been admitted 226 during the neonatal period (n=136, 44.2%). 227 The most common previously identified risk factors for sepsis other than prematurity were preterm 228 premature rupture of membranes (14.5%, n=466), prolonged rupture of membranes (>18hrs) (10.2% 229 n=328), prelabour rupture of membranes at term (9.4%, n=300), presence of an indwelling central 230 vascular catheter (8.2% n=262), intrapartum fever >38°C (3.5%, n=112), chorioamnionitis (2.8%, 231 n=75), known maternal Group B streptococcus (GBS) colonisation (1.4%, n=46) and previous surgery 232 (abdominal or for congenital malformations: 3.0%, n=95). Of note, 8.3% (n=265) had a congenital 233 anomaly (supplement table 1), and 7% (n=220) of infants were exposed to maternal HIV. 1318 234 (41.1%) sepsis episodes were healthcare-associated (occurring >48h after hospital admission). 235 Clinical and laboratory findings 236 A median of 4 (IQR 2-5) clinical signs were present at baseline, the most common being respiratory 237 (65.8%, n=2107), difficulty feeding (45.7%, n=1464), lethargy or reduced movement (35.3%, 238 n=1,131), abdominal distension (24.3%, n=777) and evidence of shock (21.3%, n=683). Signs 239 suggestive of meningitis were reported in <10% of babies (irritability, convulsions, abnormal 240 posturing, bulging fontanelle) (supplement figures 6-7). The availability of laboratory values varied 241 by site. At baseline, a base excess <-10 mmol/L was documented in 352 of 1492 with results 242 available (23.6%), lactate > 2mmol in 1034/1283 (80.6%), raised CRP > 10mg/L in 1306/2286 (57.1%), 243 abnormal white blood cell count (<4 or >20x109 cells/L) in 875/2800 (31.3%), and thrombocytopenia 244 (<150x10° cells/L) in 619/2776 (22.3%) (supplement table 2). 245 Patterns of empiric antibiotic use 246 1180 (36.8%) infants had a history of previous intravenous antibiotic treatment, and 742 (23.2%) had 247 been receiving an intravenous antibiotic in the previous 24h before starting new antibiotics for the 248 new episode of sepsis. Median time from baseline culture being taken to new intravenous antibiotic 249 treatment being started for the distinct sepsis episode was 1 hour (IQR 0-3); 2913 (90.9%) started

within 8 hours, and 228 (7.1%) within 8-24 hours (supplement figure 8).

251 There were 206 different combinations of empiric antibiotics started at baseline in this hospital-252 based cohort. These were grouped as described in the methods, and most frequent regimens are 253 reported in table 2. 25.9% (n=814) of infants were started on a WHO-recommended first line 254 penicillin-based regimen (Group 1 - Access). 13.8% (n=432) of infants were started on a WHO second 255 line cefotaxime or ceftriaxone-based combination (Group 2 - 'Low' Watch) (figure 1a). The largest 256 group (34.0%, n=1068) were started on a regimen providing partial ESBL/pseudomonal coverage 257 (piperacillin-tazobactam, ceftazidime, or fluoroguinolone based) (Group 3 – 'Medium' Watch). 258 Within Group 3 ceftazidime ± amikacin (n=436; 13.9%) and piperacillin/tazobactam±amikacin 259 (n=410; 13.1%) were prominent combinations. 18.0% (n=566) of initial regimens were carbapenem-260 based (Group 4 - 'High' Watch), among whom meropenem ± vancomycin (n=447; 14.2%) was the 261 most common combination. 1.8% (n=57) of initial regimens were classified as group 5 antibiotics 262 targeting carbapenem-resistant organisms, predominantly colistin-based (Group 5 - Reserve) (table 263 2; supplement figures 9-13). An 'Other' group (n=204) consisted of more rarely used local regimens 264 not on the WHO EMLc, or regimens which did not include a new antibiotic 'stem' that was used to define groups 1-5 (e.g. aminoglycoside or glycopeptide given alone or in combination with each 265 266 other) (supplementary figure 14). Cefoperazone/sulbactam (n=99) was the most common antibiotic 267 in this category, but was used as initial regimen only in India (n=86; 14.5%), China (n=11; 1.9%) and 268 Vietnam (n=2; 1.0%). 269 There was wide variation between sites in the frequency of empiric use of different antibiotic groups 270 (Figure 1b). Some sites used predominantly Group 1 antibiotics as the initial regimen, and others often started immediately with Group 3 or 4 regimens, or a mixture of all groups. The most 271 272 frequently prescribed empiric regimens used for healthcare associated infections (HAI) were 273 meropenem±vancomycin (28.2%, 361/1280), followed by piperacillin/tazobactam±amikacin (17.5%, 274 n=224), ceftazidime±amikacin (6.7%, n=86, colistin (4.3%, n=55) and cefoperazone/sulbactam (3.9%, 275 n=50). Ampicillin+gentamicin was the most common regimen for non-HAI (19.7%, 366/1861), 276 followed by ceftazidime±amikacin (18.8%, n=350) and piperacillin/tazobactam±amikacin (10.0%, 277 n=186) (supplement table 3). 278 Adjusting for site, predictors of starting empiric therapy with group 3-5 rather than group 1-2 279 antibiotics included lower birth weight (OR=0.57 per additional kg, 95% CI 0.47-0.69), presence of a 280 central vascular catheter (OR=3.48, 95% CI 1.74-6.94), previous antibiotics at enrolment (OR=5.71, 281 95% CI 3.73-8.77), previous culture positive sepsis (OR=25.71, 95% CI 3.00-220.7), longer time in 282 hospital (48 versus 0 hours: OR=4.41, 95% CI 3.41-5.69), previous surgery (OR=5.18, 95% CI 1.65-283 16.28) and higher sepsis severity (OR=1.27 per additional score point, 95% CI 1.16-1.40) (see 284 supplement table 4). 285 286 Antibiotic switching 287 After initial therapy, 728/2880 (25.3%) who started on Group 1-4 regimens were escalated to a 288 higher group regimen, the majority switching within the first days of treatment (supplement figures 289 15-17). 258/814 (31.7%) infants escalated from Group 1 (ampicillin/gentamicin) regimens, the 290 majority of which switched to Group 2 (cefotaxime/ceftriaxone-based) regimens (61.6%, n=159) 291 (figure 1c), 101/432 (23.4%) infants escalated from Group 2 regimens, mostly directly to a Group 4 292 carbapenem-based regimen (62.4%, n=63) rather than a Group 3 partial ESBL/pseudomonal activity 293 regimen (32.7%, n=33). 287/1068 (26.9%) escalated from group 3 regimens, and of 566 infants 294 starting treatment with carbapenems (Group 4), 82 (14.5%) escalated therapy to a colistin-295 containing regimen. Common reported reasons for first escalation of antibiotics overall included

containing regimen. Common reported reasons for first escalation of antibiotics overall included

296 clinical deterioration (65.9%, n=480), microbiology results (15.4%, n=112), and worsening 297 inflammatory biomarkers (9.8%, n=71). De-escalation of antibiotics was rare (173/2937; 5.9%). 298 Cumulative incidence of stopping intravenous treatment within 7 days from baseline culture was 299 38.9% (95% CI 37.2-40.6%) overall (Figure 1d); 45.8% (95% CI 43.8-47.6%) in pathogen-negative and 300 6.9% (95% CI 5.0-9.2%) in pathogen-positive cases. After stopping intravenous antibiotics, 350/2803 301 (12.5%) switched to oral therapy. 289 of 2803 infants who had stopped (10.3%), restarted 302 intravenous antibiotics during the original hospital stay, and a further 84 infants after discharge. 115 303 (3.4%) were still on uninterrupted antibiotic treatment at day 28. Median total number of days on 304 intravenous antibiotics during the 28 days follow-up was 8 (IQR 6-14) days (supplement figure 18). 305 Of note, intramuscular use of antibiotics was very rare (<0.1%). 306 307 Microbiology 308 Initial blood culture results were available for 3195 (99.7%) infants; 693 (21.7%) grew at least one 309 organism. Organisms identified as significant pathogens were isolated in 564/693 (>1 pathogen in 310 29) blood cultures, contaminants (presumed non-pathogens) in 117, and indeterminate in 12 311 cultures (table 1). Gram-negative and Gram-positive pathogens were found in 62.9% (355/564) and 312 34.8% (196/564) of infants, respectively (n=8 with both), and fungal pathogens in 21. Amongst 313 infants with a significant pathogen, Klebsiella pneumoniae (23.4%, n=132), Coagulase-negative 314 staphylococci (CoNS) (14.9%, n=84), Acinetobacter species (12.8%, n=72), Staphylococcus aureus 315 (9.6%, n=54), and Escherichia coli (8.3%, n=47) were the most common (table 1; supplement figure 316 19) but with differences between sites (supplement figure 20). Streptococcus agalactiae was found 317 in only 19 babies (3.4%). All the common pathogens were identified in both early and late onset 318 sepsis (figure 2), although Escherichia coli was more common in the first 3 days of life while 319 Klebsiella pneumoniae more frequent in late onset sepsis (supplement table 5). 320 58% (75/130 tested) of Klebsiella pneumoniae isolates were resistant to gentamicin, 75.0% (96/128) 321 to commonly used 3rd-generation cephalosporins (cefotaxime/ceftriaxone), 46.5% (53/114) were 322 resistant to piperacillin-tazobactam, 46.6% (48/103) to ciprofloxacin, and 32.6% (43/132) to 323 meropenem (supplementary table 6). Acinetobacter species were resistant to meropenem in 71.4% (50/70) of cases. Escherichia coli retained greater susceptibility to 3rd-generation cephalosporins 324 325 (64.4%, 29/45 susceptible), and was susceptible in 90.4% (38/42) of cases to piperacillin-tazobactam. 326 Among Gram-negatives there were important differences in susceptibility among aminoglycosides, 327 with amikacin providing significantly better activity than gentamicin (e.g. 61.5% vs 38.5% 328 susceptibility among Klebsiella pneumoniae). 329 Among 54 Staphylococcus aureus isolates, 33 (61.1%) were methicillin resistant. Staphylococcus 330 aureus and CoNS were susceptible to vancomycin in all of 42 and 73 isolates tested respectively, and 331 all 19 Streptococcus agalactiae isolates were susceptible to ampicillin. Other rarer and more site-332 specific pathogens with high rates of resistance to antibiotics included Serratia species, Burkholderia 333 species, and Elizabethkingia meningoseptica (supplement table 6). 334 1226/3204 (38.3%) infants had a cerebrospinal fluid (CSF) culture performed at baseline or during 335 the subsequent 7 days. 73/1226 (6.0%) were culture-positive, 47 with a pathogen, and 26 336 contaminant/indeterminate. Gram-negative organisms also dominated in CSF cultures (supplement 337 table 7).

339 Mortality 340 Overall, 350 infants (11.3%; 95%Cl 10.2-12.5%) died within 28 days of baseline blood culture. 341 Mortality among infants with a pathogen-positive baseline culture was 17.7% (99/564; 95%CI 14.7-342 21.1%) compared with 9.9% (250/2631; 95%CI 8.8-11.2%) in infants without pathogens (p<0.001). 343 Mortality was higher in infants with Gram-negative (21.3%; 95%CI 17.4-25.9%) or fungal pathogens 344 (38.1%; 95%Cl 21.2-61.9%) than with Gram-positive pathogens (8.5%; 95%Cl 5.3-13.5%; p<0.001). 345 Mortality was 33.3% (95%CI 23.7-45.5%) in infants with Acinetobacter spp., 21.5% (95%CI 15.4-346 29.6%) with Klebsiella pneumoniae, 21.1% (95%Cl 8.5-46.8%) with Streptococcus agalactiae, 12.8% 347 (95%CI 6.0-26.3%) with E. coli, 11.1% (95%CI 5.2-23.1%) with Staphylococcus aureus, and 3.6% 348 (95%Cl 1.2-10.8%) with CoNS (figure 3; supplement table 8). Overall, Gram-negative infections 349 accounted for 75/99 (75.8%) of culture-positive deaths, especially Klebsiella pneumoniae (n=28; 350 28.3%), and Acinetobacter spp. (n=24; 24.2%). There was significant variation in mortality between 351 different sites (Figure 5). 352 There was no significant association between time from blood culture to start of new antibiotics and 353 mortality, neither overall (HR=1.01 per additional 2 hours [95%CI 0.96-1.07]; p=0.68) nor in the 354 subgroup with no previous antibiotic exposure (HR=1.02 [95%CI 0.94-1.10]; p=0.67) (supplement 355 figure 21). 356 Discussion 357 358 In this hospital-based observational study in 11 countries across Africa, Asia, Europe and Latin 359 America we observed wide variation in antibiotic prescribing beyond WHO recommendations for 360 neonates and young infants with sepsis, with over 200 different empiric combinations, frequent 361 empiric escalation and rare de-escalation of therapy. Antimicrobial resistance was common, and 362 Gram-negative pathogens (Klebsiella and Acinetobacter), were largely resistant to WHO 363 recommended regimens. Among Gram positives, MRSA accounted for over half of Staphylococcus 364 aureus isolates. 10% of pathogen-negative, and 18% of pathogen-positive infants died, and Gram-365 negative infections were associated with the majority of pathogen-positive deaths. 366 To our knowledge this is the largest multi-country hospital based observational study of sepsis in 367 neonates and young infants to collect detailed daily prospective clinical and antimicrobial prescribing 368 data linked to microbiology and clinical outcomes. These data confirm trends in antibiotic use reported in recent point prevalence surveys in LMIC settings, 16 but this study provides evidence on 369 patterns of switching and escalation of therapy. In particular, a third of infants that had started on 370 371 WHO recommended regimens escalated to broader spectrum antibiotic regimens, and escalation 372 overall was most commonly to a carbapenem. There was also considerable use of 'carbapenem-373 sparing' regimens with 'partial' ESBL and anti-pseudomonal activity that varied between centres 374 (piperacillin-tazobactam, ceftazidime and quinolone-based regimens, often in combination with amikacin). Evidence on carbapenem-sparing regimens is limited in neonates, 26 but Pseudomonas 375 infections were rare in NeoOBS and in the recent published literature. 5,6 Notably, a small but 376 377 important proportion of infants in some sites received treatment for proven or suspected 378 carbapenem-resistant infection with colistin, for which a recommended approach to dosing and combination therapy remains unclear, and CSF penetration and side effect profile are sub-optimal.²⁷ 379 380 Some countries are also using less widely used combinations such as cefoperazone/sulbactam, for which neonatal data are limited. 28,29 381

382

383

384

385

386 387

388

389

390 391

392

393

394

395

396

397

398

399

400

401

402

403

404

405 406

407

408

409

410

411

412

413

414 415

416

417

418

419

420

421 422

423

424

425

426

427

The extent to which increasing prevalence of AMR is associated with excess mortality, and whether this may be modifiable with different antibiotic treatment strategies, is unclear in neonates and young infants. AMR has been demonstrated as an independent predictor of mortality in adults with bloodstream infections, including in LMIC settings. 30 However, data in neonates and young infants in many LMIC settings are scarce. 15,31 A limited number of largely retrospective observational studies have shown an increase in mortality particularly in association with resistant Gram negative infections^{32–35}, such as those due to organisms producing extended spectrum beta-lactamases (ESBL)^{36–39} and carbapenem resistant organisms (CRO), ^{40–43} and some suggest an increase in mortality in the absence of appropriate antimicrobial therapy. 32,44-47 A recent large multicentre neonatal sepsis study (BARNARDS) demonstrated high resistance to ampicillin + gentamicin (97% and 70%, respectively) among Gram-negative infections; however, analysis of the influence of antibiotic treatment on outcomes was confounded by country effects, and limited clinical data prevented adjusting for other important confounders. 9 Appropriate analyses of the causal relationship between discordant antibiotic treatment and mortality would need to consider baseline confounders as well as time-dependent confounding, 48 but to our knowledge this has not been done for neonatal sepsis in LMIC settings to an extent that it could inform changes to global guidance. 9,35,42,49,50 Relevant analyses in the NeoOBS cohort are ongoing. Limitations should be taken into account when considering the generalisability of these data. Most sites in NeoOBS represented secondary or tertiary hospitals in urban settings, in some cases receiving referrals after prior treatment in other hospitals. In many cases these facilities provided a higher level of care than is typical in many low resource settings. AMR may be more important, and a wider range of antibiotics may be available in these settings compared to more rural low resource settings. 51,52 This is an important bias in most studies on AMR in low resource settings, where the need for high quality microbiology means certain settings are over-represented. A significant proportion (36.8%) of infants had previously received antibiotics before the new sepsis episode, which may influence culture yield and pathogen characteristics. Selection bias was also possible beyond site selection, in particular with prospective recruitment potentially leading to a milder phenotype as infants who die rapidly with sepsis are more difficult to enrol, possibly leading to underestimation of mortality. The sites were selected to be heterogenous, with wide variation in levels of supportive care and mortality. These data highlight the major limitations of basing antibiotic recommendations on observational data alone. Analyses to determine the impact of antibiotic use on outcomes are confronted with important biases, 48 including the influence of initial sepsis severity on antibiotic choice and timing of first administration, antibiotic availability and affordability, inter-site population heterogeneity, local guidelines and microbiology, and varying levels of supportive care. In the context of increasing resistance to WHO recommended therapy for neonatal sepsis in LMIC settings, and a lack of evidence to guide optimal management due to the limitations of observational data, further randomised antibiotic trials are urgently needed. There is a very limited pipeline of new antibiotics for Gram negative infections⁵³ and future strategic trials of novel regimens need to include older off-patent antibiotics. 54,55 This study demonstrates there is no single "standard of care" in neonatal sepsis. Novel trial designs are therefore needed to define optimal treatment from a background of wide variation in empiric antibiotic prescribing and frequent switching. This study has now informed the design of the NeoSep1 trial (ISRCTN 48721236) which will use a network metaanalytic approach to rank novel off patent antibiotic combinations compared to WHO recommended and other commonly used regimens, combined with a SMART (Sequential Multiple Assessment Randomised Trial) design to allow randomisation to both empiric first and second line treatment.

Randomised Trial) design to allow randomisation to both empiric first and second line treatment.

Table 1: Baseline Characteristics and Antibiotic use

Infant characteristics			N (%) or median (IQR)
	WHO region of enrolment:	Africa	998 (31.1%)
		Americas	79 (2.5%)
		South-East Asia	1201 (37.5%)
		Europe	121 (3.8%)
		Western Pacific	805 (25.1%)
	Age at baseline (days)		5 (1, 15)
	Sex Male		1854 (57.9%)
	Female		1348 (42.1%)
	Indeterminate/intersex		2 (0.1%)
	Birth weight (grams)		2500 (1400, 3200)
	Gestational age at birth (weeks)		37 (31, 39)
	Estimated gestational age at birth, categories		
	extremely preterm (<28 weeks)		227 (7.1%)
	very preterm (28 to <32 weeks)		607 (19.0%)
	moderately preterm 32 to <37 weeks		694 (21.7%)
	term (≥37 weeks)		1674 (52.3%)
Birth history	Birth status Hospitalised	since birth	2215 (69.1%)
	Admitted fro	m home/community	989 (30.9%)
	Time from admission to enrolment (hours)		22 (1, 126)
	Mode of delivery: Vaginal		1774 (55.4%)
	Emergency caesarean section		969 (30.2%)
	Elective caesarean section		443 (13.8%)
	Congenital anomalies		265 (8.3%)
Antibiotics	On IV antibiotics in previous 24 hours		742 (23.2%)
Previous surgery	Abdominal surgery or for congenital		95 (3.0%)
Trevious surgery	malformations		, ,
Supportive care at baseline	IV fluid (supportive/feeding)		2497 (77.9%)
	Thermal care		
	Incubator care		984 (30.7%)
	Heated mattress		115 (3.6%)
	Overhead heater		(33.7%)
	Kangaroo Mother Care		163 (5.1%)
	Oxygen supplementation		1894 (59.1%)
		invasive ventilation	719 (22.4%)
	Invasive ventilation		701 (21.9%)
	Phototherapy		522 (16.3%)
	Transfusion red blood cells		221 (6.9%)
	Transfusion platelets		64 (2.0%)
	Fresh frozen plasma		118 (3.7%)
	Feeding Breast/formula/other milk		1953 (61.0%)
	TPN		527 (16.4%)
	Nasogastric tube		1432 (44.7%)
Baseline culture	Negative		2502 (78.3%)
	Contaminant (presumed non-pathogen)		117 (3.7%)
	Pathogen		564 (17.7%)
	Indeterminate		12 (0.4%)
Pathogens	Klebsiella pneumoniae		132 (4.1)
rathogens	Coagulase-negative Staphylococci		


Acinetobacter spp. *	72 (2.3)
Staphylococcus aureus	54 (1.7)
Escherichia coli	47 (1.5)
Enterobacter spp.	39 (1.2)
Serratia spp.	20 (0.6)
Streptococcus agalactiae	19 (0.6)
Other Gram-negative bacteria **	65 (2.0)
Other Gram-positive bacteria ***	42 (1.3)
Fungi ****	21 (0.7)


Note: * Acinetobacter baumannii: n=64; Acinetobacter iwoffii: n=2; unspecified: n=6. ** Enterococcus faecalis: n=14; Enterococcus faecium: n=10; Bacillus spp.: n=4; Streptococcus pneumoniae: n=3; Streptococcus pyogenes: n=3; Aerococcus viridans: n=1; Corynebacterium spp.: n=1; Dermabacter hominis: n=1; Listeria monocytogenes: n=1; Streptococcus gallolyticus: n=1; Streptococcus salivarius: n=1; Streptococcus vestibularis: n=1; Streptococcus viridans: n=1. *** Elizabethkingia meningoseptica: n=15; Burkholderia spp.: n=12; Citrobacter spp.: n=10; Elizabethkingia anophelis: n=7; Klebsiella oxytoca: n=7; Pseudomonas aeruginosa: n=5; Proteus mirabilis: n=2; Campylobacter coli: n=1; Klebsiella spp.: n=1; Morganella morgannii: n=1; Pseudomonas putida: n=1; Pseudomonas stutzeri: n=1; Salmonella spp.: n=1; Sphingomonas paucimobilis: n=1; Stenotrophomonas maltophilia: n=1. **** Candida albicans: n=13; Candida parapsilosis: n=2; Candida pelliculosa: n=2; Candida auris: n=1; Candida tropicalis: n=1; Kodamaea ohmeri: n=1; Wickerhamomyces anomalus: n=1.

Table 2: Most common antibiotic regimens in each Group


	Most common antibiotic combinations (>5% of each group)	N (%) of group
Group 1	Ampicilin + Gentamicin	403 (49.5%)
	Ampicillin + Amikacin	87 (10.7%)
	Penicillin + Gentamicin	61 (7.5%)
	Co-amoxiclav + Amikacin	59 (7.2%)
	Co-amoxiclav	55 (6.8%)
Group 2	Cefotaxime	92 (21.3%)
	Cefotaxime + Ampicillin	78 (18.1%)
	Ceftriaxone	58 (13.4%)
	Cefotaxime + Amikacin	50 (11.6%)
Group 3	Piperacillin/Tazobactam + Amikacin	356 (33.3%)
	Ceftazidime	297 (27.8%)
	Ceftazidime + Amikacin	139 (13.0%)
	Ciprofloxacin + Amikacin	58 (5.4%)
	Ceftazidime + penicillin	55 (5.1%)
Group 4	Meropenem + Vancomycin	246 (43.5%)
	Meropenem	201 (35.5%)
	Meropenem + Amikacin	49 (8.7%)
Group 5	Colistin + Meropenem	15 (26.3%)
	Colistin	13 (22.8%)
	Colistin + Meropenem + Amikacin	5 (8.8%)
	Colistin + Meropenem + Vancomycin	5 (8.8%)
	Colistin + Vancomycin	4 (7.0%)
Other	Cefoperazone/sulbactam + Amikacin	61 (29.9%)
	Cefoperazone/sulbactam	24 (11.8%)
	Moxalactam	21 (10.3%)
	Vancomycin + Gentamicin	18 (8.8%)
	Vancomycin	17 (8.3%)
	Amikacin	11 (5.4%)

Figure 1 – 1a Antibiotic AWaRe Wheel including empiric antibiotic grouping at baseline; 1b Empiric baseline therapy by site; 1c First change of initial regimen, by baseline regimen; 1d Cumulative incidence of stopping all iv antibiotics.





Group 1 = First line WHO recommended penicillin-based regimen (e.g. ampicillin and gentamicin) (Access). Group 2 = 3rd generation cephalosporin (eg cefotaxime/ceftriaxone)-based WHO regimens ('Low' Watch). Group 3 = regimens with partial anti-extended-spectrum beta-lactamase ((ESBL) or pseudomonal activity (e.g. piperacillin-tazobactam/ceftazidime/fluoroquinolone-based) ('Medium' Watch). Group 4 = Carbapenems ('High' Watch). Group 5 = Reserve antibiotics targeting carbapenem resistant organisms (e.g. colistin).









Figure 3: Mortality by pathogen in baseline blood culture



Note: Kaplan-Meier analysis, unadjusted.

Figure 4: Antibiotic resistance among leading pathogens in baseline blood culture








Figure 5: Kaplan-Meier curves for mortality, overall and by site

References

- 1. Seale, A. C. *et al.* Estimates of possible severe bacterial infection in neonates in sub-Saharan Africa, south Asia, and Latin America for 2012: a systematic review and meta-analysis. *Lancet Infect. Dis.* **14**, 731–741 (2014).
- 2. Breiman, R. F. *et al.* Postmortem investigations and identification of multiple causes of child deaths: An analysis of findings from the Child Health and Mortality Prevention Surveillance (CHAMPS) network. *PLOS Med.* **18**, e1003814 (2021).
- 3. Gabrysch, S. et al. Does facility birth reduce maternal and perinatal mortality in Brong Ahafo, Ghana? A secondary analysis using data on 119 244 pregnancies from two cluster-randomised controlled trials. *Lancet Glob. Heal.* **7**, e1074–e1087 (2019).
- 4. Fuchs, A., Bielicki, J., Mathur, S., Sharland, M. & Van Den Anker, J. N. Reviewing the WHO guidelines for antibiotic use for sepsis in neonates and children. *Paediatr. Int. Child Health* **38**, S3–S15 (2018).
- 5. Okomo, U. *et al.* Aetiology of invasive bacterial infection and antimicrobial resistance in neonates in sub-Saharan Africa: a systematic review and meta-analysis in line with the STROBE-NI reporting guidelines. *Lancet Infect. Dis.* (2019). doi:10.1016/S1473-3099(19)30414-1
- 6. Chaurasia, S. et al. Neonatal sepsis in South Asia: huge burden and spiralling antimicrobial resistance. *BMJ* **364**, k5314 (2019).

- 7. Investigators of the Delhi Neonatal Infection Study (DeNIS) collaboration. Characterisation and antimicrobial resistance of sepsis pathogens in neonates born in tertiary care centres in Delhi, India: a cohort study. *Lancet Glob. Heal.* **4**, e752–e760 (2016).
- 8. Sands, K. *et al.* Characterization of antimicrobial-resistant Gram-negative bacteria that cause neonatal sepsis in seven low- and middle-income countries. *Nat. Microbiol.* **6**, 512–523 (2021).
- 9. Thomson, K. M. *et al.* Effects of antibiotic resistance, drug target attainment, bacterial pathogenicity and virulence, and antibiotic access and affordability on outcomes in neonatal sepsis: an international microbiology and drug evaluation prospective substudy (BARNARDS). *Lancet Infect. Dis.* (2021). doi:10.1016/S1473-3099(21)00050-5
- 10. Murray, C. J. L. *et al.* Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. *Lancet* **399**, 629–655 (2022).
- 11. Laxminarayan, R. *et al.* Access to effective antimicrobials: a worldwide challenge. *Lancet* **387**, 168–175 (2016).
- 12. Dewez, J. E., Chellani, H. K., Halim, A. & Van Den Broek, N. Simplified antibiotic regimens for neonatal sepsis AFRINEST(1). *The Lancet* (2015). doi:10.1016/S0140-6736(15)00330-X
- 13. Mir, F. et al. Simplified antibiotic regimens for treatment of clinical severe infection in the outpatient setting when referral is not possible for young infants in Pakistan (Simplified Antibiotic Therapy Trial [SATT]): a randomised, open-label, equivalence trial. Lancet Glob. Heal. 5, e177–e185 (2017).
- 14. Joseph, G., da Silva, I. C. M., Wehrmeister, F. C., Barros, A. J. D. & Victora, C. G. Inequalities in the coverage of place of delivery and skilled birth attendance: analyses of cross-sectional surveys in 80 low and middle-income countries. *Reprod. Health* 13, 77 (2016).
- 15. Korang, S. K. *et al.* Antibiotic regimens for late-onset neonatal sepsis. *Cochrane Database Syst. Rev.* (2021). doi:10.1002/14651858.CD013836.pub2
- 16. Jackson, C. *et al.* Global Divergence From World Health Organization Treatment Guidelines for Neonatal and Pediatric Sepsis. *Pediatr. Infect. Dis. J.* **38**, (2019).
- 17. Folgori, L. *et al.* Tackling antimicrobial resistance in neonatal sepsis. *Lancet. Glob. Heal.* **5**, e1066–e1068 (2017).
- 18. Li, G. *et al.* Towards understanding global patterns of antimicrobial use and resistance in neonatal sepsis: insights from the NeoAMR network. *Arch. Dis. Child.* **105**, 26 LP 31 (2020).
- 19. WHO. Managing possible serious bacterial infection in young infants when referral is not feasible. (2015).
- 20. Tuzun, F. *et al.* Is European Medicines Agency (EMA) sepsis criteria accurate for neonatal sepsis diagnosis or do we need new criteria? *PLoS One* **14**, e0218002–e0218002 (2019).
- 21. Fitchett, E. J. A. *et al.* Strengthening the Reporting of Observational Studies in Epidemiology for Newborn Infection (STROBE-NI): an extension of the STROBE statement for neonatal infection research. *Lancet Infect. Dis.* **16**, e202–e213 (2016).
- 22. Harris, P. A. *et al.* Research electronic data capture (REDCap)—A metadata-driven methodology and workflow process for providing translational research informatics support. *J. Biomed. Inform.* **42**, 377–381 (2009).
- 23. Hsia, Y. et al. Use of the WHO Access, Watch, and Reserve classification to define patterns of

- hospital antibiotic use (AWaRe): an analysis of paediatric survey data from 56 countries. *Lancet Glob. Heal.* **7**, e861–e871 (2019).
- 24. Sulis, G. et al. Exposure to WHO AWaRe antibiotics and isolation of multi-drug resistant bacteria: a systematic review and meta-analysis. Clin. Microbiol. Infect. (2022). doi:10.1016/j.cmi.2022.03.014
- 25. Neal Russell*, Wolfgang Stöhr*Co-First authors, listed alphabetically et al. The NeoSep Severity and Recovery scores to predict mortality in hospitalized neonates and young infants with sepsis derived from the global NeoOBS observational cohort study. Submitt. to Plos Med. (2022).
- 26. Lutsar, I. et al. Meropenem vs standard of care for treatment of neonatal late onset sepsis (NeoMero1): A randomised controlled trial. *PLoS One* **15**, e0229380 (2020).
- 27. Nakwan, N., Chokephaibulkit, K. & Imberti, R. The Use of Colistin for the Treatment of Multidrug-resistant Gram-negative Infections in Neonates and Infants: A Review of the Literature. *Pediatr. Infect. Dis. J.* **38**, (2019).
- Ovali, F., Gursoy, T., Sari, I., Divrikli, D. & Aktas, A. Use of Cefoperazone/sulbactam in neonates. *Pediatr. Int.* **54**, 60–63 (2012).
- 29. Bortone, B. *et al.* High global consumption of potentially inappropriate fixed dose combination antibiotics: Analysis of data from 75 countries. *PLoS One* **16**, e0241899 (2021).
- 30. Stewardson, A. J. *et al.* Effect of carbapenem resistance on outcomes of bloodstream infection caused by Enterobacteriaceae in low-income and middle-income countries (PANORAMA): a multinational prospective cohort study. *Lancet. Infect. Dis.* **19**, 601–610 (2019).
- 31. Wen, S. C. H. *et al.* Gram-negative neonatal sepsis in low- and lower-middle-income countries and WHO empirical antibiotic recommendations: A systematic review and meta-analysis. *PLOS Med.* **18**, e1003787 (2021).
- 32. Peters, L. *et al.* Multiple antibiotic resistance as a risk factor for mortality and prolonged hospital stay: A cohort study among neonatal intensive care patients with hospital-acquired infections caused by gram-negative bacteria in Vietnam. *PLoS One* **14**, e0215666–e0215666 (2019).
- 33. Folgori, L. *et al.* Epidemiology and Clinical Outcomes of Multidrug-resistant, Gram-negative Bloodstream Infections in a European Tertiary Pediatric Hospital During a 12-month Period. *Pediatr. Infect. Dis. J.* **33**, (2014).
- 34. Foglia, E. E., Fraser, V. J. & Elward, A. M. Effect of Nosocomial Infections Due to Antibiotic-Resistant Organisms on Length of Stay and Mortality in the Pediatric Intensive Care Unit. *Infect. Control Hosp. Epidemiol.* **28**, 299–306 (2007).
- 35. Ivády, B. *et al.* Factors influencing antimicrobial resistance and outcome of Gram-negative bloodstream infections in children. *Infection* **44**, 309–321 (2016).
- 36. Abdel-Hady, H., Hawas, S., El-Daker, M. & El-Kady, R. Extended-spectrum β-lactamase producing Klebsiella pneumoniae in neonatal intensive care unit. *J. Perinatol.* **28**, 685 (2008).
- 37. Kayange, N., Kamugisha, E., Mwizamholya, D. L., Jeremiah, S. & Mshana, S. E. Predictors of positive blood culture and deaths among neonates with suspected neonatal sepsis in a tertiary hospital, Mwanza- Tanzania. *BMC Pediatr.* **10**, 39 (2010).
- 38. Ariffin, H. et al. Ceftazidime-resistant Klebsiella pneumoniae bloodstream infection in

- children with febrile neutropenia. Int. J. Infect. Dis. 4, 21-5 (2000).
- 39. Zaoutis, T. E. *et al.* Risk Factors for and Outcomes of Bloodstream Infection Caused by Extended-Spectrum ss-Lactamase-Producing Escherichia coli and Klebsiella Species in Children. *Pediatrics* **115**, 942–949 (2005).
- 40. Thatrimontrichai, A. *et al.* Risk Factors and Outcomes of Carbapenem-resistant Acinetobacter baumannii Bacteremia in Neonatal Intensive Care Unit: A Case-case-control Study. *Pediatr. Infect. Dis. J.* **32**, (2013).
- 41. Thatrimontrichai, A. *et al.* Risk factors and outcomes of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia in the neonate: A case-case-control study. *J. Infect. Chemother.* **22**, 444–449 (2016).
- 42. Punpanich, W., Nithitamsakun, N., Treeratweeraphong, V. & Suntarattiwong, P. Risk factors for carbapenem non-susceptibility and mortality in Acinetobacter baumannii bacteremia in children. *Int. J. Infect. Dis.* **16**, e811–e815 (2012).
- 43. Saleem, A. F., Ahmed, I., Mir, F., Ali, S. R. & Zaidi, A. K. Pan-resistant Acinetobacter Infection in Neonates in Karachi, Pakistan. *J. Infect. Dev. Ctries.* **4**, 030–037 (2010).
- 44. Cook, A. *et al.* Association of Empiric Antibiotic Regimen Discordance With 30-Day Mortality in Neonatal and Pediatric Bloodstream Infection—A Global Retrospective Cohort Study. *Pediatr. Infect. Dis. J.* **40**, (2021).
- 45. Lenglet, A., Faniyan, O. & Hopman, J. A Nosocomial Outbreak of Clinical Sepsis in a Neonatal Care Unit (NCU) in Port-Au-Prince Haiti, July 2014 September 2015. *PLoS Curr.* **10**, ecurrents.outbreaks.58723332ec0de952adefd9a9b69059 (2018).
- 46. Dramowski, A., Aucamp, M., Bekker, A. & Mehtar, S. Infectious disease exposures and outbreaks at a South African neonatal unit with review of neonatal outbreak epidemiology in Africa. *Int. J. Infect. Dis.* **57**, 79–85 (2017).
- 47. Naas, T. et al. Neonatal infections with multidrug-resistant ESBL-producing E. cloacae and K. pneumoniae in Neonatal Units of two different Hospitals in Antananarivo, Madagascar. BMC Infect. Dis. 16, 275 (2016).
- 48. Lim, C. *et al.* Effect of Delays in Concordant Antibiotic Treatment on Mortality in Patients With Hospital-Acquired Acinetobacter Species Bacteremia: Emulating a Target Randomized Trial With a 13-Year Retrospective Cohort. *Am. J. Epidemiol.* **190**, 2395–2404 (2021).
- 49. Dramowski, A. *et al.* Mortality attributable to third-generation cephalosporin resistance in Gram-negative bloodstream infections in African hospitals: a multi-site retrospective study. *JAC-Antimicrobial Resist.* **3**, (2021).
- 50. Zaoutis, T. E. *et al.* Risk factors for and outcomes of bloodstream infection caused by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species in children. *Pediatrics* **115**, 942–9 (2005).
- Panigrahi, P. et al. Neonatal sepsis in rural India: timing, microbiology and antibiotic resistance in a population-based prospective study in the community setting. *J. Perinatol.* **37**, 911–921 (2017).
- 52. Saha, S. K. *et al.* Causes and incidence of community-acquired serious infections among young children in south Asia (ANISA): an observational cohort study. *Lancet* **392**, 145–159 (2018).
- 53. Clancy, C. J. & Nguyen, M. H. It's worse than we thought: the US market for novel Gram-

- negative antibiotics. Lancet Infect. Dis. 20, 1009–1010 (2020).
- 54. Darlow, C. A. *et al.* Potential Antibiotics for the Treatment of Neonatal Sepsis Caused by Multidrug-Resistant Bacteria. *Pediatr. Drugs* **23**, 465–484 (2021).
- 55. Li, G. *et al.* The Potential Role of Fosfomycin in Neonatal Sepsis Caused by Multidrug-Resistant Bacteria. *Drugs* **77**, 941–950 (2017).